1	
V	1
•	_

## PATENT COOPERATION TREAT

# **PCT**

CODE	DATE	NTD

ANKOM 1 8 FEB 2005

GIPS

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

DATA ENTERED FINAL

		OTICOR		
Applicant's or agent's file reference FOR FURTHER AC	TION See Form F	PCT/IPEA/416		
100871-1 SE				
International application No. International filing date	(day/month/year)	Priority date (day/month/year)		
PCT/SE2003/001602 15.10.2003		18.10.2002		
International Patent Classification (IPC) or national classification as	nd IPC			
C07D 401/12		·		
Applicant				
AstraZeneca AB et al		ļ		
This report is the international preliminary examination rep     Authority under Article 35 and transmitted to the applicant	ort, established by the according to Article	is International Preliminary Examining 36.		
· · · · · · · · · · · · · · · · · · ·	s, including this cove	The state of the s		
This report is also accompanied by ANNEXES, comprising	3:	· ·		
a. (sent to the applicant and to the International		3 sheets, as follows:		
sheets of the description, claims and/or	drawings which hav	e been amended and are the basis of this report		
and/or sheets containing rectifications	authorized by this Au	nthority (see Rule 70.16 and Section 607 of the		
Administrative Instructions).	but which this Autho	rity considers contain an amendment that goes		
beyond the disclosure in the internatio	nal application as file	ed, as indicated in item 4 of Box No. 1 and the		
Supplemental Box.	60 11	and a of electronic corrier(c))		
b (sent to the International Bureau only) a total	b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer			
readable form only, as indicated in the Supple	mental Box Relating	to Sequence Listing (see Section 802 of the		
Administrative Instructions).				
4. This report contains indications relating to the following it	ems:	,		
Box No. I Basis of the report				
Box No. II Priority				
Box No. III Non-establishment of opinion w	ith regard to novelty,	inventive step and industrial applicability		
Box No. IV Lack of unity of invention				
Box No. V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain documents cited				
Box No. VII Certain defects in the internatio	nal application			
Box No. VIII Certain observations on the international application				
Date of submission of the demand	Date of completion	n of this report		
	1			
30.04.2004	02.02.200			
Name and mailing address of the IPEA/SE	Authorized office	г		
Patent- och registreringsverket	1			

Form PCT/IPEA/409 (cover sheet) (January 2004)

Facsimile No. +46 8 667 72 88

Box 5055

S-102 42 STOCKHOLM

Carolina Gómez Lagerlöf/BS

Telephone No. +46 8 782 25 00



In	ional application No.
P	CT/SE2003/001602

<u> </u>			eric of the report	
Box	No. I		asis of the report	a filed surless
1.	With s	vise indic	to the language, this report is based on the international application in the language in which it was licated under this item.	s nieu, umes
		This rep	eport is based on a translation from the original language into the following language	· ,
		П	international search (under Rules 12.3 and 23.1(b))	
		Ħ	publication of the international application (under Rule 12.4)	
		Ħ	international preliminary examination (under Rules 55.2 and/or 55.3)	
2.	furni:	shed to ti are not a	to the elements of the international application, this report is based on (replacement sheets whether the receiving Office in response to an invitation under Article 14 are referred to in this report as "of annexed to this report):	ich have been riginally filed"
		the in	nternational application as originally filed/furnished	
•	X	the de	description:	- 4/6-michad
ĺ		pages	as originalty files 1-9 as originalty files	
ĺ			received by this Authority on	
		pages	received by this Authority on	
	$\boxtimes$	the cl	claims: as originally fi	led/firmished
l		pages	csdd /together with any statement) ur	
		pages	65	
1			es 10 12	
l	_	page		
		•	drawings: as originally fi	led/furnished
Ì		page page	received by this Authority on	
1		page		
		a sex	equence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.	
3	. [	] The	e amendments have resulted in the cancellation of:	
1			the description, pages	
į.			the claims, Nos.	
			the drawings, sheets/figs	
1	٠.	F	the sequence listing (specify):	
1		=	any table(s) related to the sequence listing (specify):	
4	4. <u> </u>	ma	his report has been established as if (some of) the amendments annexed to this report and listed be lade, since they have been considered to go beyond the disclosure as filed, as indicated in the Supple	low had not bee mental Box (Ru
1		/0.	0.2(c)).	
		늗	the description, pages	
-		느	the claims, Nos.	
I			the drawings, sheets/figs	
		L	the sequence listing (specify):	
1			any table(s) related to the sequence listing (specify):	
	• If	item 4 a <sub>j</sub>	applies, some or all of those sheets may be marked "superseded."	

Form PCT/IPEA/409 (Box No. I) (January 2004)

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Internation No.

			PCT/SE2003/001602	
Box	x No. V Reasoned statement u citations and explanat	nder Article 3 ions supporti	35(2) with regard to novelty, inventive step or industrial applicabilit ng such statement	ly;
1.	Statement			
	Novelty (N)	Claims Claims	1-14	YES
	Inventive step (IS)	Claims Claims	1-14	YES NO
	Industrial applicability (IA)	Claims Claims	1-14	YES
	2. Citations and explanations (Rule 70.7) The claims relate to a process for production of 5-methoxy-2- [[(4-methoxy-3,5-dimethyl-2-pyridyl)-methyl]-thio]-1H- benzimidazole. During the search the following document were found: A WO 9722603			
Document A shows a similar process for production of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)-methyl]-thio]-1H-benzimidazole.				
The document shows the general state of the art.				
Thus, claims 1-14 are considered to fulfil the requirements of novelty, inventive step and industrial applicability.				
	• . •			
1				

Form PCT/IPEA/409 (Box No. V) (January 2004)

WO 2004/035565

PCT/SE2003/001602

10

### CLAIMS.

1. A process for the manufacture of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]-thio]-1<u>H</u>-benzimidazole of formula I

$$s \rightarrow N$$

from (4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl alcohol comprising the following reaction steps carried out in a consecutive order in one main solvent system without isolation of the intermediates formed during the process

#### Step 1:

15

20

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl alcohol (pyrmethyl alcohol) of the formula Ia

with a chloro-dehydroxylating agent, providing (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride (pyrmethyl chloride) of the formula Ib

AMENDED SHEET

WO 2004/035565

PCT/SE2003/001602

11

Step 2:

5

25

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride of the formula Ib, prepared in Step 1 above, with 2-mercapto-5-methoxybenzimidazole (metmercazole) of the formula Ic

in the presence of a base, providing 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole (pyrmetazole) of the formula I c h a r a c t e r i z e d in that the solvent system, common for the whole reaction sequence, comprises water immiscible organic solvent with a specified amount of between 0.3 and 5.5 mg water / ml water immiscible organic solvent added.

- 2. A process according to claim 1 wherein the water immiscible organic solvent is toluene.
  - 3. A process according to claim 1 wherein the water immiscible organic solvent is ethyl acetate.
- 4. A process according to claim 1, characterized in that the specified amount of water is present from the start of the reaction according to Step 1.
  - 5. A process according to any one of claims 1 and 4, characterized in that the specified amount of water is added during the charging of the chloro-dehydroxylating agent in the reaction according to Step 1.

AMENDED SHEET

WO 2004/035565

PCT/SE2003/001602

12

- 6. A process according to any one of claims 1 to 5, characterized in that the specified amount of water is added after charging of the chloro-dehydroxylating agent in the reaction according to Step 1.
- 7. A process according to claim 1, characterized in that the specified amount of water is 0.3 5.0 mg/ml of water immiscible organic solvent.
  - 8. A process according to claim 1, characterized in that the specified amount of water is 0.4 2.4 mg/ml of water immiscible organic solvent.
  - 9. A process according to claim 1, characterized in that the specified amount of water is  $1.0 2.4 \,\text{mg/ml}$  of water immiscible organic solvent.
- 10. A process according to any one of claims 1 to 9, characterized in that the reaction according to Step 1 is carried out at a temperature between -5°C and +45°C.
  - 11. A process according to any one of claims 1 to 9, characterized in that the temperature is between -5°C and +35°C.
- 20 12. A process according to any one of claims 1 to 9, characterized in that the temperature is between +10°C and +35°C.
  - 13. A process according to any one of claims 1 to 9, characterized in that the temperature is between +25°C and +35°C.
  - 14. A process according to any one of claims 1 to 13, characterized in that the chloro-dehydroxylating agent is thionyl chloride.

30

25

١O

AMENDED SHEET